Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 21;18(39):5551-9.
doi: 10.3748/wjg.v18.i39.5551.

MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors

Affiliations

MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors

Kosaburo Nakae et al. World J Gastroenterol. .

Abstract

Aim: To clarify differences in mucin phenotype, proliferative activity and oncogenetic alteration among subtypes of colorectal laterally spreading tumor (LST).

Methods: LSTs, defined as superficial elevated lesions greater than 10 mm in diameter with a low vertical axis, were macroscopically classified into two subtypes: (1) a granular type (Gr-LST) composed of superficially spreading aggregates of nodules forming a flat-based lesion with a granulonodular and uneven surface; and (2) a non-granular type (NGr-LST) with a flat smooth surface and an absence of granulonodular formation. A total of 69 LSTs, comprising 36 Gr-LSTs and 33 NGr-LSTs, were immunohistochemically stained with MUC2, MUC5AC, MUC6, CD10 (markers of gastrointestinal cell lineage), p53, β-catenin and Ki-67 antibodies, and examined for alteration in exon 1 of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and exon 15 of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) by polymerase chain reaction followed by direct sequencing.

Results: Histologically, 15 Gr-LST samples were adenomas with low-grade dysplasia (LGD), 12 were high-grade dysplasia (HGD) and 9 were adenocarcinomas invading the submucosa (INV), while 12 NGr-LSTs demonstrated LGD, 14 HGD and 7 INV. In the proximal colon, MUC5AC expression was significantly higher in the Gr-type than the NGr-type. MUC6 was expressed only in NGr-LST. MUC2 or CD10 did not differ. P53 expression demonstrated a significant stepwise increment in progression through LGD-HGD-INV with both types of LST. Nuclear β-catenin expression was significantly higher in the NGr-type. Ki-67 expression was significantly higher in the Gr-type in the lower one third zone of the tumor. In proximal, but not distal colon tumors, the incidence of KRAS provided mutation was significantly higher in the Gr-type harboring a specific mutational pattern (G12V). BRAF mutations (V600E) were detected only in two Gr-LSTs.

Conclusion: The two subtypes of LST, especially in the proximal colon, have differing phenotypes of gastrointestinal cell lineage, proliferation and activation of Wnt/β-catenin or RAS/RAF/extracellular signal-regulated kinase signaling.

Keywords: Adenoma-carcinoma sequence; Colon; Direct sequencing; Immunohistochemistry; Laterally spreading tumor; Mucin core protein; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; β-catenin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Macroscopic appearance (chromoscopic image) of laterally spreading tumors. (A) Granular type (Gr-LST) and (B) flat- or non-granular type (NGr-LST). Whole mount view of cut sections of LSTs stained with hematoxylin and eosin: (C) A Gr-LST showing tubulovillous structures with nodular surfaces and (D) an NGr-LST consisting of small tubular glands with flat surfaces. LSTs: Laterally spreading tumors.
Figure 2
Figure 2
Immunoreactive scores for MUC2, MUC5AC, MUC6 and CD10 in all (A, D, G, J), proximal (B, E, H, K) and distal (C, F, I, L) laterally spreading tumors. Gr, Gr-LST (black bar); NGr, NGr-LST (white bar). IRS: Immunoreactive score; LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; LSTs: laterally spreading tumors; Gr: Granular; NGr: Non-granular. Data are mean ± SD; a, c, e, g, i, k, m, o, q, s, u, w, yP < 0.05, MUC2: all NGr-HGD vs NGr-INV; proximal colon NGr-LGD vs NGr-HGD or NGr-INV; Gr-LGD vs Gr-HGD; distal colon Gr-LGD vs Gr-INV; NGr-HGD vs NGr-INV; MUC5AC: all Gr-LGD vs Gr-INV; distal colon NGr-INV vs NGr-HGD or NGr-LGD; MUC6: proximal colon NGr-INV vs NGr-LGD or NGr-HGD; CD10: all NGr-LGD vs NGr-HGD; proximal colon NGr-LGD vs NGr-HGD; b, d, f, h, j, l, n, p, r, tP < 0.01, MUC2: all Gr-LGD vs Gr-HGD or Gr-INV; NGr-LGD vs NGr-INV; proximal colon Gr-LGD vs Gr-INV; distal colon Gr-LGD vs Gr-HGD; MUC5AC: all Gr-LGD vs NGr-LGD; Gr-LGD vs Gr-HGD; proximal colon Gr-type vs NGr-type; Gr-LGD vs NGr-LGD; Gr-LGD vs Gr-INV.
Figure 3
Figure 3
Immunoreactive scores for p53 (A) and nuclear β-catenin (B), and labeling indices for Ki-67 in the lower zone (C) in all laterally spreading tumors. Gr, Gr-LST (black bar); NGr, NGr-LST (white bar); LSTs: laterally spreading tumors. Data are mean ± SD; a, c, eP < 0.05, p53: Gr-HGD vs Gr-INV; nuclear β-catenin: Gr-type vs NGr-type; Ki-67, Gr-type vs NGr-type; b, d, f, h, j, l, nP < 0.01, p53: NGr-LGD vs NGr-INV; Gr-LGD vs Gr-HGD or Gr-INV; nuclear β-catenin: Gr-LGD vs Gr-HGD or Gr-INV: Gr-LGD vs NGr-LGD; Ki-67, Gr-LGD vs NGr-INV. IRSs: Immunoreactive scores; LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; Gr: Granular; NGr: Non-granular; LI: Labeling indice.
Figure 4
Figure 4
Histology and immunohistochemistry of laterally spreading tumors. Immunoreactive scores (IRSs) for Gr-LGD: MUC2, 4 points; MUC5AC, 2 points; MUC6, 0 points; CD10, 0 points; p53, 0 points; nuclear β-catenin, 0 points. IRSs for NGr-LGD: MUC2, 3 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 0 points; p53, 0 points; nuclear β-catenin, 1 points. IRSs for Gr-HGD: MUC2, 1 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 1 points; p53, 1 points; nuclear β-catenin, 1 points. IRSs for NGr-HGD: MUC2, 2 points; MUC5AC, 1 points; MUC6, 1 points, CD10, 1 points; p53, 1 points; nuclear β-catenin, 2 points. IRSs for Gr-INV: MUC2, 1 points; MUC5AC, 1 points; MUC6, 0 points, CD10, 1 points; p53, 4 points; nuclear β-catenin, 1 points. IRSs for NGr-INV: MUC2, 1 points; MUC5AC, 0 points; MUC6, 2 points, CD10, 2 points; p53, 2 points; nuclear β-catenin, 2 points (H and E, ×80; immunoperoxidase: MUC2, MUC5AC and MUC6, ×100; CD10 and p53, ×120; β-catenin, ×300); LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; Gr: Granular; NGr: Non-granular.
Figure 5
Figure 5
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and v-raf murine sarcoma viral oncogene homologue B1 mutational patterns in laterally spreading tumors. D: Aspartic acid; E: Glutamic acid; G: Glycine; S: Serine; V: Valine; Black box: Mutated case; White box: Non-mutated case; LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; Gr: Granular; NGr: Non-granular; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF: v-raf murine sarcoma viral oncogene homologue B1.
Figure 6
Figure 6
Alterations of expression of mucin core protein, p53 and β-catenin, cell proliferation and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations in malignant transformation of laterally spreading tumors. Large arrow: Marked upregulation; Medium arrow: Moderate upregulation; Small arrow: Mild upregulation; ++: Frequently mutated; +: Infrequently mutated; -: Not mutated; LGD: Adenoma with low grade dysplasia; HGD: Adenoma with high grade dysplasia; INV: Adenocarcinoma invading into submucosa; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; Gr: Granular; NGr: Non-granular.

Similar articles

Cited by

References

    1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532. - PubMed
    1. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer. 1992;70:1727–1731. - PubMed
    1. Wong NA, Pignatelli M. Beta-catenin--a linchpin in colorectal carcinogenesis? Am J Pathol. 2002;160:389–401. - PMC - PubMed
    1. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999;59:1442–1444. - PubMed
    1. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401–1408. - PubMed

Publication types

MeSH terms